» Articles » PMID: 24131545

Severe Asymptomatic Non-alcoholic Fatty Liver Disease in Routine Diabetes Care; a Multi-disciplinary Team Approach to Diagnosis and Management

Abstract

Objectives: To prospectively use a non-invasive algorithm to identify asymptomatic, advanced non-alcoholic fatty liver disease (NAFLD) in a secondary care diabetes clinic and to determine the short-term effect of a multi-disciplinary team (MDT) approach in a liver clinic.

Research Design And Methods: NAFLD Fibrosis Score (NFS) was calculated in 64 asymptomatic patients with type 2 diabetes. Advanced fibrosis was identified using transient elastography and confirmed with liver biopsy. In a subsequent retrospective study, 95 patients newly referred to the NAFLD MDT clinic were investigated and the impact of the MDT approach assessed.

Results: 25/64 (39.0%) of patients with diabetes had a low NFS (<-1.455). 39/64 (61.0%) patients had a high or indeterminate NFS and were referred for review in the NAFLD MDT clinic, of which 23/39 attended for assessment. 19/23 (82.6%) were diagnosed with NAFLD, of which 6/19 (31.6%) patients had a positive transient elastography (≥8 kPa). Liver biopsy confirmed advanced fibrosis in 5/6 cases, with moderate fibrosis in 1 case. In the retrospective study, 65/95 (68.4%) new referrals to the NAFLD MDT clinic had a diagnosis of NAFLD. Over a median 98 days (IQR 70-182) follow-up, there was a significant improvement in weight (-0.8 kg; P = 0.024), total cholesterol (-0.2 mmol/L; P = 0.044), ALT (alanine transmaminase, -12.5 IU/L; P < 0.001) and GGT (gammu-glutamyl transferase, -13.0 IU/L; P < 0.0001). 7/28 (25%) of patients with diabetes achieved >5% weight loss.

Conclusions: A significant proportion of asymptomatic patients attending type 2 diabetes clinics have undiagnosed advanced NAFLD fibrosis. An MDT approach to NAFLD results in short-term improvements in metabolic and liver parameters.

Citing Articles

Protective effects of against hepatocyte apoptosis and liver fibrosis induced by high palmitic acid diet.

Tsai W, Situmorang J, Kuo W, Kuo C, Lin S, Huang C Front Pharmacol. 2025; 15():1438997.

PMID: 39850574 PMC: 11755097. DOI: 10.3389/fphar.2024.1438997.


Automated Fibrosis-4 Index: Simplifying Non-Alcoholic Fatty Liver Disease for Diabetologists.

Ismail M, Al Argan R, Elamin Y, Makki M, Alsheekh L, Alelyani J Medicina (Kaunas). 2024; 60(8).

PMID: 39202559 PMC: 11356356. DOI: 10.3390/medicina60081278.


Progressive changes in platelet counts and Fib-4 scores precede the diagnosis of advanced fibrosis in NASH patients.

Zijlstra M, Gampa A, Joseph N, Sonnenberg A, Fimmel C World J Hepatol. 2023; 15(2):225-236.

PMID: 36926233 PMC: 10011908. DOI: 10.4254/wjh.v15.i2.225.


The correlation between triiodothyronine and the severity of liver fibrosis.

He W, Huang C, Wang L, Su W, Wang S, Huang P BMC Endocr Disord. 2022; 22(1):313.

PMID: 36503486 PMC: 9743744. DOI: 10.1186/s12902-022-01228-8.


Multi-disciplinary clinic models for the management of non-alcoholic fatty liver disease.

Zoncape M, Liguori A, Tsochatzis E Hepatobiliary Surg Nutr. 2022; 11(4):586-591.

PMID: 36016750 PMC: 9396080. DOI: 10.21037/hbsn-22-58.


References
1.
Tahrani A, Ali A, Raymond N, Begum S, Dubb K, Mughal S . Obstructive sleep apnea and diabetic neuropathy: a novel association in patients with type 2 diabetes. Am J Respir Crit Care Med. 2012; 186(5):434-41. PMC: 3443800. DOI: 10.1164/rccm.201112-2135OC. View

2.
Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View

3.
Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L . Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006; 6:6. PMC: 1386692. DOI: 10.1186/1471-230X-6-6. View

4.
Roulot D, Czernichow S, Le Clesiau H, Costes J, Vergnaud A, Beaugrand M . Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol. 2008; 48(4):606-13. DOI: 10.1016/j.jhep.2007.11.020. View

5.
Casey S, Kemp W, McLean C, Topliss D, Adams L, Roberts S . A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver disease. Scand J Gastroenterol. 2012; 47(7):836-41. DOI: 10.3109/00365521.2012.677955. View